Atrial fibrillation, often associated with coronary artery disease, requires a combination of anticoagulation and antiplatelet therapy to reduce the risk of stroke and cardiovascular events. However, the combination of antithrombotic therapy increase the risk of bleeding, and need to weigh the advantages and disadvantages of antithrombotic therapy. At present, there is still lack of large-scale clinical evidence. This review summarizes the current evidences published and recommendations in consensus and guidelines at home and abroad.